Viral Vector Reformulated for Ovarian Cancer CAR T-cell Therapy, Anixa Says

Viral Vector Reformulated for Ovarian Cancer CAR T-cell Therapy, Anixa Says
Anixa Biosciences and Moffitt Cancer Center have completed the development and validation of a new viral vector designed to improve the efficacy of their immunotherapy candidate for ovarian cancer, based on CAR T-cell technology. The vector's manufacturing is now ongoing under Good Manufacturing Practice conditions — those ensuring that medicines are consistently produced in high quality, from batch to batch — and is expected to take approximately three months. At this point, Anixa and Moffitt remain on track to file an Investigational New Drug with the U.S. Food and Drug Administration in 2020. Clinical trials are expected to begin in 2021 "We are pleased to have completed this first milestone in our development program and remain confident in our previously stated development timeline," Amit Kumar, PhD, president and CEO of Anixa, said in a
Subscribe or to access all post and page content.